Search results for "pancreatic disease"

showing 10 items of 78 documents

Recurrence of Acute Gallstone Pancreatitis and Relationship with Cholecystectomy or Endoscopic Sphincterotomy

2004

To determine the prevalence of recurrence of gallstone pancreatitis, its clinical features, and the presence of prognostic factors of recurrence.From January 1, 2000 to August 31, 2003, 233 patients admitted with acute gallstone pancreatitis (AGP) were prospectively studied. Patients were divided into two groups: recurrent and nonrecurrent group. Clinical, analytical, radiological, prognostic parameters, and severity (Atlanta criteria) were assessed, along with the performance of cholecystectomy or endoscopic sphincterotomy (ES). Clinical features of recurrence were analyzed. Univariate (chi(2), Student's t-test) and multivariate tests were performed. Statistical significance was assumed if…

Malemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentGallstonesSeverity of Illness IndexSphincterotomy EndoscopicRecurrenceRisk FactorsSeverity of illnessPrevalenceHumansMedicineCholecystectomyProspective StudiesProspective cohort studyAgedChi-Square DistributionHepatologymedicine.diagnostic_testbusiness.industryGallbladderGeneral surgeryGastroenterologyMiddle AgedPrognosismedicine.diseaseSurgeryEndoscopyLogistic Modelsmedicine.anatomical_structurePancreatitisAcute DiseasePancreatitisFemaleCholecystectomybusinessChi-squared distributionThe American Journal of Gastroenterology
researchProduct

Value of magnetic-resonance cholangio-pancreatography (MRCP) after unsuccessful endoscopic-retrograde cholangio-pancreatography (ERCP).

1997

Background and Study Aims: The present study tries to evaluate the success rate of MRCP when two attempts by experts to perform ERCP in a center failed. Patients and Methods: From March 1996 to December 1996 thirteen patients fulfilled the inclusion criteria. The MR cholangiopancreatograms were acquired using commercially available software in a clinical MR scanner (Magnetom Expert 1T-Scanner, Siemens, Erlangen, Germany). MRCP utilized heavily T2-weighted turbo-spin echo sequences with fat supression (HASTE). Maximum intensity projection (MIP) of the pancreatic duct and biliary tree was then carried out. Additionally, T1-weighted sequences were obtained using the breath-hold technique. Resu…

Malemedicine.medical_specialtyPercutaneousPancreatic pseudocystBiliary Tract DiseasesmedicineImage Processing Computer-AssistedHumansMedical diagnosisAgedPancreatic ductAged 80 and overCholangiopancreatography Endoscopic Retrogrademedicine.diagnostic_testbusiness.industryBile ductGastroenterologyPancreatic DiseasesMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureMaximum intensity projectionFemaleRadiologybusinessEndoscopic retrograde cholangio-pancreatographyEndoscopy
researchProduct

Thymidine-dependent Staphylococcus aureus small-colony variants: human pathogens that are relevant not only in cases of cystic fibrosis lung disease.

2008

ABSTRACT We report the isolation of thymidine-dependent small-colony variants (TD-SCVs) of Staphylococcus aureus from unusual infection sites of patients with chronic soft tissue infection, tympanitis, bronchitis, peritonitis, and septicemia. Furthermore, we provide evidence that the essential growth factor for TD-SCVs, i.e., thymidine, and its metabolite dTMP are present in various human specimens.

Microbiology (medical)AdultMaleStaphylococcus aureusPancreatic diseaseCystic FibrosisPeritonitisPeritonitismedicine.disease_causeCystic fibrosischemistry.chemical_compoundSepsisPulmonary fibrosismedicineHumansBronchitisChildbusiness.industryRespiratory diseaseBacteriologyPneumoniaMiddle AgedStaphylococcal Infectionsmedicine.diseasechemistryStaphylococcus aureusImmunologyBronchitisFemalebusinessThymidineThymidineJournal of clinical microbiology
researchProduct

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

2006

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentpancreatic cancerAntineoplastic AgentschemotherapyAntimetaboliteDeoxycytidinechemistry.chemical_compoundHemoglobinsLeukocyte CountInternal medicinePancreatic cancerClinical StudiesmedicineHumansIn patientAgedNeoplasm StagingChemotherapyDose-Response Relationship Drugbusiness.industryPlatelet CountgemcitabineMiddle Agedmedicine.diseaseepirubicinGemcitabineSurgeryPancreatic NeoplasmsOncologychemistryDeoxycytidineFemalebusinessEpirubicinmedicine.drugBritish Journal of Cancer
researchProduct

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyur…

1996

BACKGROUND To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase II trial has been performed by the Southern Italy Oncology Group with the aim of evaluating the clinical effectiveness and tolerability of weekly 5-fluorouracil (5-FU) in modulation with intravenous (i.v.) high dose levofolinic acid and oral hydroxyurea. METHODS A total of 70 patients fulfilling the standard eligibility for a Phase II study were enrolled in the trial. Forty patients had advanced pancreatic adenocarcinoma and 30 had advanced gallbladder carcinoma. The treatment sched…

OncologyMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticPancreatic diseaseAntidotesLeucovorinPhases of clinical researchAdministration OralAntineoplastic AgentsAdenocarcinomaGastroenterologyDrug Administration ScheduleMetastatic carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansHydroxyureaInfusions IntravenousAgedbusiness.industryGallbladderCarcinomaRemission InductionLeukopeniaMiddle Agedmedicine.diseasePancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyTolerabilityItalyInjections IntravenousDisease ProgressionAdenocarcinomaFemaleGallbladder NeoplasmsFluorouracilbusinessProgressive diseaseCancer
researchProduct

Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells

2010

Pancreatic cancer is one of the most aggressive human malignancies with an increasing incidence worldwide. Despite an increase in the number of systemic treatments available for pancreatic cancer, the impact of therapy on the clinical course of the disease has been modest, underscoring an urgent need for new therapeutic options. Although selective cyclooxygenase-2 inhibitors have been demonstrated to have cancer-preventive effects, the mechanism of their effects is not clearly known. Moreover, there have been no unbiased studies to identify novel molecular targets of NS-398 regarding pancreatic cancer. Here we undertook a gene expression profiling study to identify novel molecular targets m…

Pancreatic diseaseDown-RegulationApoptosisBiologyDownregulation and upregulationCell Line TumorPancreatic cancermedicineHumansNitrobenzenesCell ProliferationOligonucleotide Array Sequence AnalysisPharmacologySulfonamidesCell growthGene Expression ProfilingCancermedicine.diseaseAryl hydrocarbon receptorUp-RegulationPancreatic NeoplasmsCTGFGene expression profilingImmunologyCancer researchbiology.proteinEuropean Journal of Pharmacology
researchProduct

Inkarzeration eines Pankreassteinfragmentes im distalen Pankreasgang nach Therapie durch extrakorporale Stoßwellenlithotripsie (ESWL)

2001

A partial or total absence of stones in pancreaticolithiasis therapy can be reached by using ESWL. We report on a patient who happened to get an incarceration of a fragment in the distal pancreatic duct after having been treated by ESWL without a previous sphincterotomy to the ductus Wirsungianus. This emphasizes the recommendation to carry out a papillotomy of the pancreatic main duct before applying ESWL to pancreatic stones.

Pancreatic ductmedicine.medical_specialtyPancreatic diseasebusiness.industrymedicine.medical_treatmentGastroenterologyLithotripsymedicine.diseaseMain ductSurgerymedicine.anatomical_structurePancreatic stoneMedicinePancreatitisPancreatic stonesbusinessZeitschrift für Gastroenterologie
researchProduct

Laser fragmentation of pancreatic duct stones using a rhodamine laser with an automatic stone-tissue detection system. Basic in-vitro studies

1997

OBJECTIVES The aim of our study was to examine the suitability of a rhodamine 6G laser with an integrated stone-tissue detection system (STDS) for fragmenting pancreatic stones. METHODS A total of 64 pancreatic duct stones were measured for weight, diameter, main chemical components and in some cases for their computerized tomography density. Recognition of all stones was checked with the standard STDS or a prototype version. Number of fragmentation pulses, total fragmentation energies and correlation with the individual stone parameters were determined. The quality of the tissue-detection mode was evaluated in postmortem pancreata. RESULTS The standard STDS detected only 45% of the pancrea…

Pathologymedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentIn Vitro TechniquesLithotripsySensitivity and SpecificityCalculilaw.inventionRhodamine 6GRhodaminechemistry.chemical_compoundlawmedicineHumansPancreatic stonesFragmentation (cell biology)Pancreatic ductHepatologyRhodaminesbusiness.industryPancreatic DuctsGastroenterologyPancreatic DiseasesEquipment DesignLithotripsy LaserLasermedicine.diseasemedicine.anatomical_structurechemistryTomography X-Ray ComputedNuclear medicinebusinessEuropean Journal of Gastroenterology & Hepatology
researchProduct

Effectiveness of Enteric-Coated Preparations on Nutritional Parameters in Cystic Fibrosis

1988

To evaluate the effectiveness of enteric-coated pancreatic enzyme supplements in comparison to conventional preparations of ingested enzyme on growth and nutritional parameters of patients with cystic fibrosis, we conducted a long-term study involving 40 patients. The data reproduced here were recorded after 6 months of therapy with powder-containing capsules or with enteric-coated products. Fat absorption was estimated by measurement of steatorrhoea with the steatocrit method. All parameters studied improved after enteric-coated pancreatic enzyme therapy, with a statistically significant increase in weight, cholesterol and haemoglobin values. Furthermore, the number of patients with positi…

medicine.medical_specialtyChemotherapyPancreatic diseaseCholesterolbusiness.industrymedicine.medical_treatmentRespiratory diseaseGastroenterologymedicine.diseaseGastroenterologyEnteric coatingCystic fibrosischemistry.chemical_compoundEndocrinologymedicine.anatomical_structurechemistryOral administrationInternal medicinemedicinebusinessPancreasmedicine.drugDigestion
researchProduct

Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery

2016

Objective: To provide evidence-based recommendations for the management of exocrine pancreatic insufficiency (EPI) after pancreatic surgery. Background: EPI is a common complication after pancreatic surgery but there is certain confusion about its frequency, optimal methods of diagnosis, and when and how to treat these patients. Methods: Eighteen multidisciplinary reviewers performed a systematic review on 10 predefined questions following the GRADE methodology. Six external expert referees reviewed the retrieved information. Members from Spanish Association of Pancreatology were invited to suggest modifications and voted for the quantification of agreement. Results: These guidelines analyz…

medicine.medical_specialtyEvidence-based practicediagnosisMEDLINEGuidelines030230 surgeryGastroenterologyPancreatic surgerysurgery03 medical and health sciencesPostoperative Complications0302 clinical medicineInternal medicineparasitic diseasesmedicineHumansGuidelines Management Exocrine Pancreatic Insufficiency Pancreatic SurgerypancreasguidelinesExocrine pancreatic insufficiencyPancreatic SurgeryConfusionpancreatic exocrine insufficiencyEvidence-Based Medicinetreatmentbusiness.industryPancreatic DiseasesEvidence-based medicinemedicine.diseaseManagementSurgerySpainpancreaticPractice Guidelines as TopicExocrine Pancreatic Insufficiency030211 gastroenterology & hepatologySurgerymedicine.symptomComplicationOptimal methodsbusinessAnnals of Surgery
researchProduct